Injection Devices
Vetter Performs Extraordinarily With Six Wins in the 12th Annual CDMO Leadership Awards
Vetter recently earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service. In addition, the…
Stevanato Group Collaborates With Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market
The companies will offer an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain….
Jubilant HollisterStier Announces New President & Upcoming Availability of Expanded Production Capacity for Sterile Injectables
Jubilant HollisterStier (JHS) recently announced the appointment of Chris Preti as President. He brings more than 25 years of broad pharmaceutical industry experience to JHS.…
Nemera & Nelson Labs Europe Strengthen Partnership to Offer Integrated Services to Customers
This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers – accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice….
Choosing the Best Drug Stability Solution for a Parental Product
The development of an injectable drug product always comes with the question of the best approach to retaining the product’s stability. We asked Dr. David Brett, Product and Service Manager at Vetter, what must be considered to deal with the….
MARKET TRENDS - Emerging Trends in Injectable Drug Formulation & Delivery
Martin Gonzalez, PhD, details current trends in sterile injectable formulations and delivery devices and highlights the challenges pharma and its CDMO partners are facing bringing emerging parenteral breakthroughs to patients.
Vaxxas Initiates Phase 1 Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent Delivered Using High-Density Microarray Patch
Vaxxas recently announced the initiation of a Phase 1 clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’…
MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Gerresheimer & Corning Announce Joint Venture to Meet Growing Demand for Velocity® Vials, Accelerating the Delivery of Life-Saving Treatments
The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity® Vial technology platform, helping set a new standard for the industry….
Stevanato Group Collaborates With Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma
Leading drug containment provider to release a unique offering including both COP and COC pre-fillable syringes (PFS), adding to its existing glass PFS portfolio, providing customers with the broadest choice for PFS….
Gerresheimer Presents its New Clinical Trial Kit to Accelerate Drug Development
Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in nest and tub or tray…
Start-Up Innovation at Pharmapack 2023
Pharmapack Europe 2023 returns to its traditional February timing for the first time since the start of the pandemic and provides the industry with a vital early window into many of tomorrow’s technologies that improve patient experience, adherence, and delivery…..
Brand New State-of-the-Art Nemera Manufacturing Facility Inaugurated in Poland
Based in Szczecin, this facility will significantly boost Nemera’s manufacturing capabilities and bring more drug delivery device solutions to patients…..
Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access
CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….
Scaling Up Capacity, Eitan Medical Opens New Manufacturing Facility Bolstered by Semi-Automated Production Lines
Eitan Medical recently announced today the opening of its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its…
ROUNDTABLE DISCUSSION - Which Trends Will Have the Most Impact on Drug Development in 2023?
Contributor Cindy H. Dubin posed this question to life science leaders during a recent roundtable discussion, and one common theme is the focus on sustainability in pharmaceutical development.
Gerresheimer to Expand Significantly in High Value Solutions & Further Accelerates its Sustainable Profitable Growth
Gerresheimer AG recently reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The company continues to execute consistently its formula g strategy…
2023 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
Meridian Medical Technologies & Kindeva Drug Delivery to Combine
Meridian Medical Technologies recently announced it will combine with Kindeva Drug Delivery to create a leading global drug-device combination product Contract Development and….
Tjoapack Strengthens its Injectables Offering With Addition of Prefilled Syringes Assembly & Packaging Services
Global pharmaceutical contract packaging organization (CPO), Tjoapack has invested in a new high-speed packaging line for prefilled syringes and vials at its production facilities in…
What are Injection Devices?
Drug delivery devices are the physical agents that are included in the drug delivery system. There are a multitude of devices that people interact with every day which fall under this category. In modern pharmaceuticals, novel drug delivery devices and combination products are being designed for a number of reasons, including giving patients the ability to self-administer some medications at home, which can help them adhere to recommended regimens.
Evolution of Injection Devices
With modern technology and medicine, the combination product market is evolving. Any combination device, especially drug device combination devices, must follow strict guidelines. Thanks to advancements in engineering, an increasing number of drug delivery devices are being developed as electromechanical devices linked to apps in order to provide patients with more supervision when administering medications at home. Some of these medical apps may receive feedback from the device to track how much drug is being administered and how often, provide patients with dosing reminders and connect clinicians with this information so they can monitor patient compliance. The drug delivery devices that so many patients depend on must adhere to regulatory standards. There are strict guidelines for all methods of drug delivery, such as needle-based, aerosol, and needle-free injectors.
Smart devices, interconnectivity, and related technology provide real-time data to healthcare providers for analysis, but these device additions should not increase risks, including patient understanding of treatment delivery, or jeopardize compliance. Data collection needs to be “passive” to the patient. In other words, invisible to the patient’s use of the device so that the collected data provides a true benefit to the end user. If these design considerations can be implemented without impacting the patient or how they administer and receive treatment, then smart devices can provide advantages to the patient and the industry.
Injection Device Global Market Trends
The global injectable drug delivery devices market is expected to show significant growth in the coming years as manufacturers introduce technological advancements and product innovation meant to improve convenience, compliance, and ease of administration of parenterals. Additionally, the increasing preference for at-home self-injection is driving the market as patients prefer to continue to avoid healthcare settings post-COVID. With all of this taken into account, one market study predicts the global market to reach almost $26 billion by 2025, up from $15 billion in 2020. However, another report values the global market at $42.76 billion in 2021 and expects it to reach $50.9 billion in 2025.
How the numbers will play out is yet to be determined, but the studies do highlight the focus on single-use and reusable systems. Disposable-use prefilled syringes (PFS) are increasingly used due to the prevalence of chronic diseases and the growing number of biologics best delivered by syringes. Single-use autoinjectors are also poised to experience increased demand, particularly with the growing pervasiveness of anaphylaxis disorders. Autoinjectors also provide a convenient alternative to manual syringe injections for subcutaneous administration.
Reusable Injection Devices
Pen injectors with prefilled cartridges have also proven to be a viable alternative to syringes. These injectors can perform hundreds of injections, with patients controlling the speed of delivery to minimize pain or discomfort during use.
Making injection devices partially reusable is a cost-saving strategy. Ideally, the device’s mechanism and/or electronics are the reusable parts of the system – as these are often the costliest – and the drug containers and needle are one-time use.
Another cost-saving strategy that several large pharmaceutical companies are deploying is to develop a device platform for multiple drug products in their portfolio. This allows them to spend resources on a single significant development program, for one optimal injection device, which then requires minimal customization for each sub-sequent product line.
Despite efforts to make better, safer, simpler injection devices, patient adherence is still a challenge associated with self-administration. This has resulted in the emergence of smart devices, such as wearable injectors, which share patient data with healthcare providers to ensure compliance. And while it is expected this sector will continue to grow, some industry insiders warn against making these devices too intrusive.